Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
23.85
+1.15 (5.07%)
At close: Feb 17, 2026, 4:00 PM EST
24.32
+0.47 (1.97%)
After-hours: Feb 17, 2026, 6:18 PM EST
Innoviva Employees
Innoviva had 127 employees as of December 31, 2024. The number of employees increased by 15 or 13.39% compared to the previous year.
Employees
127
Change (1Y)
15
Growth (1Y)
13.39%
Revenue / Employee
$3,059,220
Profits / Employee
$1,002,709
Market Cap
1.78B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 493 |
| Agios Pharmaceuticals | 488 |
| MannKind | 407 |
| Ardelyx | 395 |
| Zymeworks | 263 |
| Tango Therapeutics | 155 |
| Precigen | 143 |
| Pharvaris | 118 |
INVA News
- 2 months ago - U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents - Business Wire
- 2 months ago - US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections - Reuters
- 2 months ago - Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea - Business Wire
- 3 months ago - Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference - Business Wire
- 3 months ago - Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 4 months ago - Antheia Appoints Eric d'Esparbes as Chief Financial Officer - PRNewsWire
- 4 months ago - Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 - Business Wire
- 4 months ago - Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 - Business Wire